TY - JOUR
T1 - Promotion of Knee Cartilage Degradation by IκB Kinase ε in the Pathogenesis of Osteoarthritis in Human and Murine Models
AU - Uchida, Taisuke
AU - Akasaki, Yukio
AU - Sueishi, Takuya
AU - Kurakazu, Ichiro
AU - Toya, Masakazu
AU - Kuwahara, Masanari
AU - Hirose, Ryota
AU - Hyodo, Yuki
AU - Tsushima, Hidetoshi
AU - Lotz, Martin K.
AU - Nakashima, Yasuharu
N1 - Funding Information:
Supported by AMED (grant GAQQ030001), a Grant‐in‐Aid for Early‐Career Scientists (FAG1K16658) from the Japan Society for the Promotion of Science, The Nakatomi Foundation, the Ogata Science Promotion Foundation, and Japan Orthopedics and Traumatology Foundation. In addition, this study was supported by the Research Support Center, Research Center for Human Disease Modeling, Kyushu University Graduate School of Medical Sciences.
Publisher Copyright:
© 2022 American College of Rheumatology.
PY - 2023/6
Y1 - 2023/6
N2 - Objective: NF-κB signaling is an important modulator in osteoarthritis (OA), and IκB kinase ε (IKKε) regulates the NF-κB pathway. This study was undertaken to identify the functional involvement of IKKε in the pathogenesis of OA and the effectiveness of IKKε inhibition as a modulatory treatment. Methods: IKKε expression in normal and OA human knee joints was analyzed immunohistochemically. Gain- or loss-of-function experiments were performed using human chondrocytes. Furthermore, OA was surgically induced in mice, followed by intraarticular injection of BAY-985, an IKKε/TANK-binding kinase 1 inhibitor, into the left knee joint every 5 days for 8 weeks. Mice were subsequently examined for histologic features of cartilage damage and inflammation. Results: IKKε protein expression was increased in human OA cartilage. In vitro, expression levels of OA-related factors were down-regulated following knockdown of IKKε with the use of small interfering RNA in human OA chondrocytes or following treatment with BAY-985. Conversely, IKKε overexpression significantly increased the expression of OA-related catabolic mediators. In Western blot analysis of human chondrocytes, IKKε overexpression increased the phosphorylation of IκBα and p65. In vivo, intraarticular injection of BAY-985 into the knee joints of mice attenuated OA-related cartilage degradation and hyperalgesia via NF-κB signaling. Conclusion: These results suggest that IKKε regulates cartilage degradation through a catabolic response mediated by NF-κB signaling, and this could represent a potential target for OA treatment. Furthermore, BAY-985 may serve as a major disease-modifying compound among the drugs developed for OA. (Figure presented.).
AB - Objective: NF-κB signaling is an important modulator in osteoarthritis (OA), and IκB kinase ε (IKKε) regulates the NF-κB pathway. This study was undertaken to identify the functional involvement of IKKε in the pathogenesis of OA and the effectiveness of IKKε inhibition as a modulatory treatment. Methods: IKKε expression in normal and OA human knee joints was analyzed immunohistochemically. Gain- or loss-of-function experiments were performed using human chondrocytes. Furthermore, OA was surgically induced in mice, followed by intraarticular injection of BAY-985, an IKKε/TANK-binding kinase 1 inhibitor, into the left knee joint every 5 days for 8 weeks. Mice were subsequently examined for histologic features of cartilage damage and inflammation. Results: IKKε protein expression was increased in human OA cartilage. In vitro, expression levels of OA-related factors were down-regulated following knockdown of IKKε with the use of small interfering RNA in human OA chondrocytes or following treatment with BAY-985. Conversely, IKKε overexpression significantly increased the expression of OA-related catabolic mediators. In Western blot analysis of human chondrocytes, IKKε overexpression increased the phosphorylation of IκBα and p65. In vivo, intraarticular injection of BAY-985 into the knee joints of mice attenuated OA-related cartilage degradation and hyperalgesia via NF-κB signaling. Conclusion: These results suggest that IKKε regulates cartilage degradation through a catabolic response mediated by NF-κB signaling, and this could represent a potential target for OA treatment. Furthermore, BAY-985 may serve as a major disease-modifying compound among the drugs developed for OA. (Figure presented.).
UR - http://www.scopus.com/inward/record.url?scp=85147259859&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147259859&partnerID=8YFLogxK
U2 - 10.1002/art.42421
DO - 10.1002/art.42421
M3 - Article
C2 - 36530063
AN - SCOPUS:85147259859
SN - 2326-5191
VL - 75
SP - 937
EP - 949
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
IS - 6
ER -